Oral treatment for advanced blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an oral drug combination for people with advanced myeloproliferative neoplasms (MPNs), which are blood cancers. The treatment may help control the disease and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have an advanced MPN (like myelofibrosis, polycythemia vera, or essential thrombocythemia) that is progressing, or you have chronic myelofibrosis with some blast cells in your blood.
- You can swallow pills and weigh at least 41 kg (about 90 pounds).
- Your liver and kidney function must be adequate, as shown by blood tests.
- If you are of childbearing potential, you must agree to use birth control and have a negative pregnancy test.
- You have not had certain other treatments recently (like venetoclax or more than 2 cycles of a hypomethylating agent).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral medications for people with myelofibrosis, a type of bone marrow cancer. It may be an option if you have not been helped by standard JAK inhibitor therapy or if you have never tried one.
This trial tests a new drug called TQ05105 to see if it can help people with a blood-marrow disease called myelofibrosis. The study focuses on patients whose condition is moderate to severe and measures how well the drug works and how safe it is.
This trial tests two new medicines, selinexor and pacritinib, for people with myelofibrosis who have low blood counts and have not yet tried JAK inhibitor therapy. The goal is to see if this combination helps reduce spleen size and improve blood counts.
This trial combines two drugs, bomedemstat and momelotinib, to treat myelofibrosis, a rare blood cancer. It aims to see if the combination helps improve blood counts and reduce symptoms when momelotinib alone isn't working well enough.
This trial tests an oral combination of two drugs (THU and decitabine) for people with myelodysplastic syndromes (MDS) whose disease has come back or not responded to at least one prior standard treatment. The goal is to see if it can help control the disease.
This Phase 2 trial tests whether adding decitabine to one of three targeted medicines (ruxolitinib, fedratinib, or pacritinib) can improve outcomes in people with advanced myeloproliferative neoplasms that are progressing to a blast phase. It may help control the disease by combining blood-cancer chemotherapy with drugs that block disease-driving signaling.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.